Drug Trial Radar · NCT00997035
The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo
Last checked: Nov 19, 2026Latest source record: Feb 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
May 2010
Primary completion
Jan 2016
Study completion Mar 2016
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aravind Eye Hospitals, India; Dartmouth-Hitchcock Medical Center; Lumbini Eye Institute and Research Centre; Bharatpur Eye Hospital; National Eye Institute (NEI)
- First posted
- Oct 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if the addition of oral voriconazole to topical treatment regimens results in lower rates of perforation in severe fungal corneal ulcers.
Conditions
- Corneal Ulcer
- Eye Infections, Fungal
Interventions
VoriconazoleDrug
1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment. 5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment. 400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing \<40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment.
PlaceboDrug
1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment. 5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment. Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Perforation or Therapeutic Penetrating KeratoplastyTime frame: 3 months from enrollment
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Proctor Foundation, UCSF
San Francisco, California
Aravind Eye Hospital
Coimbatore, Tamil Nadu, India
Aravind Eye Hospitals
Madurai, Tamil Nadu, India
Aravind Eye Hospital
Pondicherry, Tamil Nadu, India
Aravind Eye Hospital
Tirunelveli, Tamil Nadu, India
Bharatpur Eye Hospital
Bharatpur, Chitwan, Nepal
Lumbini Eye Institute
Siddharthanagar, Lumbini, Nepal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.